The hidden engineering behind every pill you’ve ever taken
The size of a tablet feels like a design decision. It isn’t. It is an inheritance — from a 19th-century press, a century of standardised tooling, and a regulatory preference for whatever already exists.
By Ibumix · 7-minute read
The illusion of design
You have felt it before: the tablet that is a little too large, a little too dry, a little too rigid. You hesitate, reach for water, try again. What you almost never do is ask the obvious question — who decided this should be the size of your medicine?
It feels as though someone must have. The dimensions seem deliberate, as if they emerged from careful ergonomic study. They did not. Tablet size is not the product of a single human-centred decision. It is the accumulation of thousands of constraints layered over nearly two centuries — manufacturing, material physics, regulation and legacy infrastructure — almost none of them about you.
No one decided the size of your medicine. It simply settled.
Most of your tablet isn’t the medicine
Start with what is actually in your hand. In a great many tablets, the active drug is a minority of the mass — frequently between 10% and 50% of it, and sometimes far less. The rest is excipient: fillers to add bulk, binders to hold the shape, disintegrants to make it break apart, lubricants to stop it sticking to the machine.
This is not waste. The drug alone usually cannot flow through high-speed machinery, compress into a stable object, and then reliably fall apart again in the body. So the industry builds a scaffold around it. The tablet you swallow is mostly that scaffold — a structural compromise wrapped around a small amount of medicine.
The man who invented that scaffold was trying to do the opposite.
The machine came first
In December 1843 a British artist named William Brockedon — not a pharmacist — filed a patent with the wonderful title “Shaping Pills, Lozenges, and Black Lead by Pressure in Dies.” His problem was not medicine at all: he wanted to reconstitute the powdered graphite falling from his pencils. His press compacted powder into a solid under a single blow, with a minimum of added material. The compressed tablet was born as a way to use less scaffolding, not more.
What followed was industrialisation. Brockedon’s press became the rotary compression machine — descendants of that same mechanism now stamp out tablets by the thousand per minute. They run on dies that fix the size and shape and punches that compress the powder, and they work best within a narrow set of standardised tooling sizes: roughly 6 mm for small tablets, 8–10 mm for standard oral doses, 12 mm and above for large ones.
Changing those dimensions is expensive — new tooling, new validation, a new manufacturing setup. So the industry did what industries do when change is costly. It standardised — not around the human throat, but around the machine.
The physics that pushes size upward
Even setting the machinery aside, physics imposes its own floor. A tablet has to survive compression, packaging, transport and handling without cracking or crumbling. Yet the same object must disintegrate quickly and dissolve predictably once swallowed. It has to be two contradictory things at once.
Strong enough to survive the world. Weak enough to fall apart inside you.
Reconciling that paradox demands a minimum thickness, a particular density, a certain structural integrity — and every one of those requirements pushes the tablet larger, not smaller. The size you struggle with is partly the price of mechanical durability the drug never needed and you never asked for.
The human enters last
Only after dose, excipients, machinery and physics have all had their say does the patient finally enter the equation — and the evidence is not subtle. The US Food and Drug Administration, in its guidance on the physical attributes of tablets and capsules, noted that tablets larger than 8 mm in diameter draw increased swallowing complaints, recommended that the largest dimension should not exceed 22 mm, and observed that oval tablets pass through the oesophagus faster than round ones of similar weight.
The need is large. The same agency estimated that more than 16 million Americans have some difficulty swallowing, and that as many as 40% of adults report difficulty swallowing tablets and capsules at some point. The groups most affected are the ones who take the most medicine: older adults, children, and anyone with dysphagia.
The industry’s response has been real but cosmetic — rounded edges, capsule shapes, smooth film coatings. But coatings add thickness, and thickness adds size. The result is a loop that defeats itself:
Make the tablet easier to swallow, and you make it bigger. Make it bigger, and you make it harder to swallow.
The cost no one counts
A tablet that is hard to swallow is not merely unpleasant; it is a quiet driver of medicines not being taken. Patients skip doses, delay them, or crush and split them — destroying a modified-release coating, delivering a dangerous bolus, or simply making the medicine unpalatable enough to abandon. For a modified-release product, crushing can turn a careful 12-hour release into a single uncontrolled dose. The failure hides in plain sight, logged as “non-adherence” rather than what it often is: a design problem with the dosage form.
And it falls hardest where it matters most. Tablets are the most widely used medicine format on earth, and the people who struggle with them most — the old, the very young, the swallowing-impaired — are precisely the people who depend on them most.
The deeper flaw: dose tied to physical form
Behind the question of size sits the assumption the tablet quietly enforces: that dose must be bound to physical mass. Need more drug, and the answer is a bigger object. But people are not standardised — they differ in weight, metabolism, absorption and disease — while the tablet hands everyone the same rigid unit. It is an elegant solution for the production line and a blunt one for biology.
The smartest fix is to shrink the tablet
The industry has not been blind to this. Its most serious answer to the size problem is to make the tablet tiny. Mini-tablets — typically 1–3 mm across, often around 2 mm, taken several at a time — have moved from curiosity to fast-growing field in two decades. In a landmark paediatric study, 2 mm mini-tablets were accepted more readily than syrup by children aged six months to six years, even the youngest infants. The European Medicines Agency has since approved mini-tablet products, including an orodispersible enalapril for paediatric heart failure and a controlled-release melatonin for childhood insomnia. They even gesture at flexible dosing: adjust the dose by counting units, rather than splitting a tablet.
This is real progress — arguably the most patient-centred thing tablet engineering has done in a generation. But see clearly what it changes and what it does not. A mini-tablet is still a compressed solid that must disintegrate and dissolve. It still ties dose to physical units — many small ones now, instead of one large one. It still needs excipient scaffolding, and still waits on the dissolution step that paces absorption. It makes the tablet far easier to swallow without ever asking whether the medicine needs to be a tablet at all. It is a better answer to the old question — not a different question.
What settles can be unsettled
Imagine designing medicine today with none of this inheritance — no 19th-century press, no validated tooling, no regulatory muscle-memory. You would not bind dose to the size of an object. You would not require anyone to swallow a compressed solid. You would not accept dissolution as an unavoidable bottleneck. You would design for absorption rather than compression, for precision rather than standardisation, for patients rather than production lines.
And you would arrive at a different question from the one the industry has answered for 180 years. Not how big a tablet should be — but why there is a tablet at all.
The tablet was never truly decided. It simply settled — and what settles can be unsettled.
That is where the next generation of drug delivery begins. Ibumix starts one step before the tablet: with the dose carried in a liquid — a measured oral dose, even a spray — so the amount of medicine is set by chemistry, not by the size of the thing in your hand, and the body can absorb it without first dismantling a compressed solid. The tablet was a brilliant answer to a 19th-century question. The question has changed.
About Ibumix
Ibumix is developing a series of new liquid drug delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- William Brockedon’s 1843 tablet-press patent (“Shaping Pills, Lozenges, and Black Lead by Pressure in Dies”) — Brockedon, British Patent, 1843–44; see William Brockedon, Wikipedia. https://en.wikipedia.org/wiki/William_Brockedon
- Tablets >8 mm draw increased swallowing complaints; largest dimension ≤22 mm; oval faster oesophageal transit — FDA Guidance for Industry: Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules. https://www.fda.gov/media/161902/download
- More than 16 million Americans have difficulty swallowing; up to ~40% report difficulty swallowing pills — FDA, as above; cited in FDA tablet-size guidance materials.
- Mini-tablets are a fast-growing field; 2 mm mini-tablets accepted better than syrup in young children, including infants — Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics, Pharmaceutics 2022 (PMC8779937). https://pmc.ncbi.nlm.nih.gov/articles/PMC8779937/
- EMA-approved mini-tablet products (orodispersible enalapril; controlled-release melatonin) — European Medicines Agency authorisations (Aqumeldi; Slenyto).
- Active drug is frequently a minority of tablet mass; excipients provide flow, compaction and disintegration — Pharmaceutical formulation literature (Aulton’s Pharmaceutics).
Part of the Ibumix series on the tablet’s limits. Start with the overview: Why the tablet is pharma’s bottleneck.